Meta-Analysis Finds No Increase in Cognitive Decline with Statins

By Kelly Young

Published data do not indicate that statins pose an increased risk for cognitive impairment, according to a meta-analysis in the Annals of Internal Medicine. In 2012, the FDA said that statins may be linked to memory loss or confusion.

Researchers assessed 25 studies that looked at cognition in patients on statins. Based on low- to moderate-quality evidence, they found that statins were not associated with increased risk for Alzheimer's disease, dementia, or mild cognitive impairment.

Their analysis of FDA postmarketing surveillance databases found similar rates of cognitive-related adverse events for statins, losartan, and clopidogrel, all around 1.9 per million prescriptions.

The authors conclude: "Published data do not suggest an adverse effect of statins on cognition; however, the strength of available evidence is limited, particularly with regard to high-dose statins."